# CinCor Pharma Inc. (CINC)

Source: https://www.quantisnow.com/company/CINC
Generated: 2026-11-10T10:58:46.507Z

- Ticker: CINC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2022
- Website: https://www.cincor.com

## About

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

## Latest CINC news and filings

- 2024-10-30 10:00 UTC [Axonis Therapeutics Announces $115 Million Series A Financing](https://www.quantisnow.com/insight/axonis-therapeutics-announces-115-million-series-a-financing-5742507)
- 2024-08-01 12:00 UTC [venBio Raises $528 Million Venture Capital Fund Focused on Life Science Companies](https://www.quantisnow.com/insight/venbio-raises-528-million-venture-capital-fund-focused-on-life-5637065)
- 2023-05-12 12:00 UTC [Earnings Date] [Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/impel-pharmaceuticals-announces-first-quarter-2023-financial-results-and-provides-4492889)
- 2023-03-23 14:19 UTC [5AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough Science](https://www.quantisnow.com/insight/5am-ventures-celebrates-20th-fda-product-approval-investing-in-breakthrough-4240133)
- 2023-03-03 15:06 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-cincor-pharma-inc-amendment-4158888)
- 2023-03-01 18:38 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-cincor-pharma-inc-amendment-4144466)
- 2023-02-28 21:30 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-cincor-pharma-inc-amendment-4136581)
- 2023-02-28 21:29 UTC [SEC Form 4] [SEC Form 4 filed by 5am Partners Vi, Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-5am-partners-vi-llc-4136546)
- 2023-02-28 21:16 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-cincor-pharma-inc-amendment-4136292)
- 2023-02-28 02:15 UTC [SEC Form 4] [SEC Form 4: Healy James returned 19,608 shares to the company and sold $85,920 worth of shares (6,000 units at $14.32), closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-healy-james-returned-19608-shares-to-the-4127362)
- 2023-02-27 22:10 UTC [SEC Form 4] [SEC Form 4: Freeman Mason returned 40,000 shares to the company and sold $91 worth of shares (6 units at $15.21), closing all direct ownership in the company to satisfy withholding tax](https://www.quantisnow.com/insight/sec-form-4-freeman-mason-returned-40000-shares-to-the-4126338)
- 2023-02-24 23:40 UTC [SEC Form 4] [SEC Form 4 filed by Allison David D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-allison-david-d-4118368)
- 2023-02-24 23:40 UTC [SEC Form 4] [SEC Form 4 filed by Ignelzi Troy A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-ignelzi-troy-a-4118366)
- 2023-02-24 23:38 UTC [SEC Form 4] [SEC Form 4: Kalb Michael Wayne returned 202,437 shares to the company, closing all direct ownership in the company](https://www.quantisnow.com/insight/sec-form-4-kalb-michael-wayne-returned-202437-shares-to-4118357)
- 2023-02-24 23:37 UTC [SEC Form 4] [SEC Form 4 filed by Lee June](https://www.quantisnow.com/insight/sec-form-4-filed-by-lee-june-4118354)
- 2023-02-24 23:36 UTC [SEC Form 4] [SEC Form 4: Pearce Catherine returned 15,000 shares to the company, closing all direct ownership in the company (tax withholding)](https://www.quantisnow.com/insight/sec-form-4-pearce-catherine-returned-15000-shares-to-the-4118347)
- 2023-02-24 23:35 UTC [SEC Form 4] [SEC Form 4 filed by Thero John F](https://www.quantisnow.com/insight/sec-form-4-filed-by-thero-john-f-4118345)
- 2023-02-24 23:34 UTC [SEC Form 4] [SEC Form 4: De Garidel Marc returned 200,000 shares to the company, closing all direct ownership in the company to cover taxes](https://www.quantisnow.com/insight/sec-form-4-de-garidel-marc-returned-200000-shares-to-4118343)
- 2023-02-24 14:19 UTC [SEC Form 8-K] [CinCor Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cincor-pharma-inc-filed-sec-form-8-k-completion-of-acquisition-4113438)
- 2023-02-24 14:07 UTC [SEC Form 25-NSE filed by CinCor Pharma Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-cincor-pharma-inc-4113345)
- 2023-02-24 11:09 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-cincor-pharma-inc-amendment-4112087)
- 2023-02-24 11:03 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-cincor-pharma-inc-amendment-4112047)
- 2023-02-23 11:07 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-cincor-pharma-inc-amendment-4103688)
- 2023-02-23 11:01 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-cincor-pharma-inc-amendment-4103611)
- 2023-02-21 13:51 UTC [SEC Form 8-K] [CinCor Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/cincor-pharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-4089764)
- 2023-02-21 13:20 UTC [Market Insight] [CinCor Pharma Announces Receipt Of Minutes From End-Of-Phase 2 Meeting With The U.S. Food And Drug Administration On Planned Phase 3 Program Of Baxdrostat](https://www.quantisnow.com/insight/cincor-pharma-announces-receipt-of-minutes-from-end-of-phase-2-meeting-4089390)
- 2023-02-21 13:00 UTC [CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat](https://www.quantisnow.com/insight/cincor-pharma-announces-receipt-of-minutes-from-end-of-phase-2-meeting-4089018)
- 2023-02-15 21:51 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-cincor-pharma-inc-amendment-4072857)
- 2023-02-14 19:30 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by CinCor Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-cincor-pharma-inc-4061407)
- 2023-02-13 21:28 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-cincor-pharma-inc-amendment-4050851)
- 2023-02-13 18:33 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by CinCor Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-cincor-pharma-inc-4048438)
- 2023-02-09 13:33 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-cincor-pharma-inc-amendment-4028495)
- 2023-02-03 22:21 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-cincor-pharma-inc-amendment-4004367)
- 2023-02-03 21:39 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by CinCor Pharma Inc. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-cincor-pharma-inc-amendment-4003628)
- 2023-01-31 01:08 UTC [SEC Form 4] [SEC Form 4: De Garidel Marc was granted 200,000 shares, increasing direct ownership by 1,600% to 212,500 units](https://www.quantisnow.com/insight/sec-form-4-de-garidel-marc-was-granted-200000-shares-3975426)
- 2023-01-31 01:07 UTC [SEC Form 4] [SEC Form 4: Pearce Catherine was granted 15,000 shares, increasing direct ownership by 11% to 155,149 units](https://www.quantisnow.com/insight/sec-form-4-pearce-catherine-was-granted-15000-shares-increasing-3975423)
- 2023-01-31 01:04 UTC [SEC Form 4] [SEC Form 4: Kalb Michael Wayne was granted 177,000 shares, increasing direct ownership by 696% to 202,437 units](https://www.quantisnow.com/insight/sec-form-4-kalb-michael-wayne-was-granted-177000-shares-3975420)
- 2023-01-31 01:03 UTC [SEC Form 4] [SEC Form 4: Freeman Mason was granted 40,000 shares, increasing direct ownership by 1,600% to 42,500 units](https://www.quantisnow.com/insight/sec-form-4-freeman-mason-was-granted-40000-shares-increasing-3975418)
- 2023-01-23 14:14 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9 filed by CinCor Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9-filed-by-cincor-pharma-inc-3938950)
- 2023-01-23 13:12 UTC [SEC Schedule TOT] [SEC Form SC TO-T filed by CinCor Pharma Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-t-filed-by-cincor-pharma-inc-3938272)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CINC
- Earnings history: https://www.quantisnow.com/earnings/CINC
- Dividend history: https://www.quantisnow.com/dividends/CINC
- Insider transactions: https://www.quantisnow.com/insiders/CINC
- Options chain: https://www.quantisnow.com/options/CINC
- SEC 8-K filings only: https://www.quantisnow.com/company/CINC/8-k
- RSS and alerts for CINC: https://www.quantisnow.com/docs/rss-feeds.md